November 11, 2026 | LL&S in the News
Ron Lanton III, Senior Partner at Lanton, Lanton & Sosa Law PLLC, participated in a November 5 webinar hosted by Managed Healthcare Executive and Drug Topics examining the consequences of the 2026 midterm elections for federal healthcare policy.
The discussion was moderated by Peter Wehrwein, Managing Editor of Managed Healthcare Executive, and included Theresa Carnegie, a healthcare and pharmaceutical supply chain attorney at Mintz, and Alicia Silver, Vice President of Market Access Policy Strategy at ADVI Health.
The panel examined the policy questions facing Congress and the Trump administration following the elections, including Medicaid funding, Affordable Care Act subsidies, pharmaceutical pricing, and the potential for additional congressional oversight.
The discussion also addressed the administration's most-favored-nation drug pricing policies and how changes in congressional leadership could affect the direction of federal healthcare policy.
For healthcare providers, pharmaceutical manufacturers, insurers, and other industry participants, the new congressional environment raises questions about which policy changes can advance through legislation and which will remain under executive branch authority.
On November 7, Managed Healthcare Executive published Peter Wehrwein's recap of the discussion, identifying key issues that healthcare organizations should follow as the new Congress prepares to convene in January.
Read the original article by Peter Wehrwein:
8 Takeaways From the MHE and Drug Topics Post-Midterms Webinar
Lanton, Lanton & Sosa Law advises healthcare organizations, pharmaceutical and biotechnology companies, and professional associations on healthcare regulation, government affairs, commercial transactions, and related legal matters.